Camille Lehuédé
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Camille Lehuédé has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Aude-Christine Guédon
Institut National D’excellence en Santé et Services Sociaux (INESSS), Montreal, QC H3A 2S9, Canada
1 shared publication - Catherine Truchon
Institut National D’excellence en Santé et Services Sociaux (INESSS), Quebec City, QC G1V 4M3, Canada
1 shared publication - Erin Strumpf
Department of Economics and Department of Epidemiology, Biostatistics, and Occupational Health, McGill University , Montreal
1 shared publication - Ferdaous Roussafi
Institut National D’excellence en Santé et Services Sociaux (INESSS), Montreal, QC H3A 2S9, Canada
1 shared publication - Gino Boily
Institut National D’excellence en Santé et Services Sociaux (INESSS), Montreal, QC H3A 2S9, Canada
1 shared publication - Jim Boulanger
Institut National D’excellence en Santé et Services Sociaux (INESSS), Quebec City, QC G1V 4M3, Canada
1 shared publication
Latest Publications
- Open Access
- 26 October 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (11) , 8043-8073
Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada
EGFR tyrosine kinase inhibitors (EGFR-TKIs) are breakthrough palliative treatments for advanced lung cancer patients with tumors harboring mutations in the EGFR gene. Using healthcare administrative data, three cohorts were created to describe the use of three EGFR-TKIs that are publicly funded in Quebec for specific indications (i.e., 1st-line gefitinib, 1st-line afatinib, and post-EGFR-TKI osimertinib). The main objective was to compare overall survival (OS) among patients receiving these treatments to those in previous experimental and real-world studies. The patients who received EGFR-TKIs for indications of interest between 1 April 2001, and 31 March 2019 (or 31 March 2020, for post-EGFR-TKI osimertinib) were included to estimate the Kaplan-Meier-based median OS for each cohort. An extensive literature search was conducted to include comparable studies. For the gefitinib 1st-line (n = 457), the afatinib 1st-line (n = 80), and the post-EGFR-TKI osimertinib (n = 119) cohorts, we found a median OS (in months) of 18.9 (95%CI: 16.3–21.9), 26.6 (95%CI: 13.7-NE) and 19.9 (95%CI: 17.4-NE), respectively. Out of the 20 studies that we retained from the literature review and where comparisons were feasible, 17 (85%) had similar OS results, which further confirms the value of these breakthrough therapies in real-world clinical practice.
- 26 October 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (11) , 8043-8073
Open AccessAdvanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada
EGFR tyrosine kinase inhibitors (EGFR-TKIs) are breakthrough palliative treatments for advanced lung cancer patients with tumors harboring mutations in the EGFR gene. Using healthcare administrative data, three cohorts were created to describe the use of three EGFR-TKIs that are publicly funded in Quebec for specific indications (i.e., 1st-line gefitinib, 1st-line afatinib, and post-EGFR-TKI osimertinib). The main objective was to compare overall survival (OS) among patients receiving these treatments to those in previous experimental and real-world studies. The patients who received EGFR-TKIs for indications of interest between 1 April 2001, and 31 March 2019 (or 31 March 2020, for post-EGFR-TKI osimertinib) were included to estimate the Kaplan-Meier-based median OS for each cohort. An extensive literature search was conducted to include comparable studies. For the gefitinib 1st-line (n = 457), the afatinib 1st-line (n = 80), and the post-EGFR-TKI osimertinib (n = 119) cohorts, we found a median OS (in months) of 18.9 (95%CI: 16.3–21.9), 26.6 (95%CI: 13.7-NE) and 19.9 (95%CI: 17.4-NE), respectively. Out of the 20 studies that we retained from the literature review and where comparisons were feasible, 17 (85%) had similar OS results, which further confirms the value of these breakthrough therapies in real-world clinical practice.